Hear From Dr. Ron Tutrone, Clinical Principal investigator
Dr. Ronald Tutrone has authored numerous articles in the urology literature. He has been principal investigator in more than 200 clinical research trials, including a recent trial involving the ExoDx Prostate (EPI) test published in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of the exosome based ExoDx™ Prostate (IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10ng/mL.
The study demonstrated that EPI delivered improved patient outcomes over standard of care in a real-world clinical setting that included 72 urologists, 24 sites and more than 1000 patients. The study is the first ever prospective, multi-center, randomized prostate biomarker trial with a blinded control arm conducted in a clinical utility setting. The study was a collaboration between the largest urology practice in Maryland, Chesapeake Urology, and CareFirst BlueCross BlueShield.
This webinar is appropriate for Urologists, Primary Care Providers, Payors, and other health professionals. Request the paper.
Webinar: How the ExoDx Prostate Test Impacts Urology Practice in a Real-World Clinical Setting
"From a clinical perspective, deferring biopsy can help a patient avoid the undesirable complications from a biopsy, such as pain, hematuria, infection and potentially hospitalization. Many patients are frightened to undergo biopsy procedure; however, introducing an EPI result not only improved compliance to proceed to biopsy, but detected more clinically significant cancers that might have been missed under the standard of care paradigm."
Dr. Tutrone earned his Bachelor of Science degree in chemistry from the College of the Holy Cross in Worcester, MA. He continued his education and obtained his MD at UMDNJ-Robert Wood Johnson Medical School. Dr. Tutrone did his residency at Brigham and Women’s Hospital in Boston, MA.
Dr. Tutrone's clinical interests include treatment of urologic malignancies including kidney, bladder and prostate; laparoscopic treatment of renal and adrenal tumors; kidney stone treatment; urinary incontinence in men and women; and prostate disorders. He also performs the UroLift procedure for the treatment of BPH/enlarged prostate. He has been voted a "Top Doctor" by Baltimore magazine numerous times, and a "Super Doctor" for Urology in the Washington Post Magazine Washington, DC, Northern Virginia and Baltimore.